However, this mechanism is expected to result into a negative correlation of TILs-PD-1/TCs-PD-L1 expression and survival, as it was reported, e.g. for renal cell carcinoma, breast cancer, non-small cell lung cancer [24] and osteosarcoma [26]. This evidence concerns the gene PDCD1 and breast carcinoma.